Freenome Reports Updated CRC Blood Test Validation Results
The updated SimpleScreen test showed 80.4% colorectal cancer sensitivity at 90% specificity. Sensitivity was 18.2% for advanced precancerous lesions and 41.9% for high-grade dysplasia.
The updated SimpleScreen test showed 80.4% colorectal cancer sensitivity at 90% specificity. Sensitivity was 18.2% for advanced precancerous lesions and 41.9% for high-grade dysplasia.